Cargando…

Identification of subgroups within a Japanese older adult population for whom statin therapy is effective in reducing mortality

Use of statins for primary prevention can reduce all-cause mortality in Asian elderly populations, but their effect and the specific effective subgroups in the elderly Japanese population remain unclear. This study examined the relationship between statin therapy for primary prevention and mortality...

Descripción completa

Detalles Bibliográficos
Autores principales: Funaki, Daito, Kaneda, Hideaki, Miyakoshi, Akinori, Saito, Kohei, Sasaki, Hatoko, Nakatani, Eiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691679/
https://www.ncbi.nlm.nih.gov/pubmed/38039298
http://dx.doi.org/10.1371/journal.pone.0295052
_version_ 1785152785550934016
author Funaki, Daito
Kaneda, Hideaki
Miyakoshi, Akinori
Saito, Kohei
Sasaki, Hatoko
Nakatani, Eiji
author_facet Funaki, Daito
Kaneda, Hideaki
Miyakoshi, Akinori
Saito, Kohei
Sasaki, Hatoko
Nakatani, Eiji
author_sort Funaki, Daito
collection PubMed
description Use of statins for primary prevention can reduce all-cause mortality in Asian elderly populations, but their effect and the specific effective subgroups in the elderly Japanese population remain unclear. This study examined the relationship between statin therapy for primary prevention and mortality reduction in older Japanese adults, and investigated the effective subgroups. The cohort study was conducted using the Shizuoka Kokuho Database (SKDB). Data were compared between the statin-treated group and a non-statin-treated (control) group using the inverse probability of treatment weighting (IPTW) method. In the SKDB cohort aged ≥65 years, new statin use was associated with a decreased risk of all-cause mortality (hazard ratio, 0.40; 95% confidence interval [CI], 0.33–0.48) after IPTW adjustment. The risk difference for mortality at 5 years in the statin-treated group compared with that in the control group was 0.05 (95% CI, 0.04–0.06), and the number needed to treat was 21.20 (95% CI, 18.10–24.70). In conclusion, statin use for primary prevention in older adults may reduce the risk of all-cause mortality in the population without atherosclerotic disease. Furthermore, statin use for primary prevention is feasible in patients aged 75 to <85 years and in patients with comorbidities such as diabetes, or dementia.
format Online
Article
Text
id pubmed-10691679
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-106916792023-12-02 Identification of subgroups within a Japanese older adult population for whom statin therapy is effective in reducing mortality Funaki, Daito Kaneda, Hideaki Miyakoshi, Akinori Saito, Kohei Sasaki, Hatoko Nakatani, Eiji PLoS One Research Article Use of statins for primary prevention can reduce all-cause mortality in Asian elderly populations, but their effect and the specific effective subgroups in the elderly Japanese population remain unclear. This study examined the relationship between statin therapy for primary prevention and mortality reduction in older Japanese adults, and investigated the effective subgroups. The cohort study was conducted using the Shizuoka Kokuho Database (SKDB). Data were compared between the statin-treated group and a non-statin-treated (control) group using the inverse probability of treatment weighting (IPTW) method. In the SKDB cohort aged ≥65 years, new statin use was associated with a decreased risk of all-cause mortality (hazard ratio, 0.40; 95% confidence interval [CI], 0.33–0.48) after IPTW adjustment. The risk difference for mortality at 5 years in the statin-treated group compared with that in the control group was 0.05 (95% CI, 0.04–0.06), and the number needed to treat was 21.20 (95% CI, 18.10–24.70). In conclusion, statin use for primary prevention in older adults may reduce the risk of all-cause mortality in the population without atherosclerotic disease. Furthermore, statin use for primary prevention is feasible in patients aged 75 to <85 years and in patients with comorbidities such as diabetes, or dementia. Public Library of Science 2023-12-01 /pmc/articles/PMC10691679/ /pubmed/38039298 http://dx.doi.org/10.1371/journal.pone.0295052 Text en © 2023 Funaki et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Funaki, Daito
Kaneda, Hideaki
Miyakoshi, Akinori
Saito, Kohei
Sasaki, Hatoko
Nakatani, Eiji
Identification of subgroups within a Japanese older adult population for whom statin therapy is effective in reducing mortality
title Identification of subgroups within a Japanese older adult population for whom statin therapy is effective in reducing mortality
title_full Identification of subgroups within a Japanese older adult population for whom statin therapy is effective in reducing mortality
title_fullStr Identification of subgroups within a Japanese older adult population for whom statin therapy is effective in reducing mortality
title_full_unstemmed Identification of subgroups within a Japanese older adult population for whom statin therapy is effective in reducing mortality
title_short Identification of subgroups within a Japanese older adult population for whom statin therapy is effective in reducing mortality
title_sort identification of subgroups within a japanese older adult population for whom statin therapy is effective in reducing mortality
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691679/
https://www.ncbi.nlm.nih.gov/pubmed/38039298
http://dx.doi.org/10.1371/journal.pone.0295052
work_keys_str_mv AT funakidaito identificationofsubgroupswithinajapaneseolderadultpopulationforwhomstatintherapyiseffectiveinreducingmortality
AT kanedahideaki identificationofsubgroupswithinajapaneseolderadultpopulationforwhomstatintherapyiseffectiveinreducingmortality
AT miyakoshiakinori identificationofsubgroupswithinajapaneseolderadultpopulationforwhomstatintherapyiseffectiveinreducingmortality
AT saitokohei identificationofsubgroupswithinajapaneseolderadultpopulationforwhomstatintherapyiseffectiveinreducingmortality
AT sasakihatoko identificationofsubgroupswithinajapaneseolderadultpopulationforwhomstatintherapyiseffectiveinreducingmortality
AT nakatanieiji identificationofsubgroupswithinajapaneseolderadultpopulationforwhomstatintherapyiseffectiveinreducingmortality